Observed arrival · 2026-10-01
MarshyOS: diligence beyond the status screen
A life-sciences diligence studio that assesses drug assets by tracing claims across trial records, papers, and linked databases.
- For
- Life-sciences investors evaluating drug assets
- Worth noticing
- The sample separates two early-stopped factor XI trials and links cited findings to ClinicalTrials.gov records.
Field notes
The page says its source pool includes 596,685 registered trials, 1,283,901 indexed clinical and mechanistic papers, and 16 linked databases covering areas such as patents, exclusivity, labels, payer spend, and health technology assessments. In a sample factor XI analysis, OCEANIC-AF (NCT05643573) reports stroke or systemic embolism rates of 1.3% versus 0.4% on apixaban; the AZALEA-TIMI 71 excerpt reports reduced bleeding. Record links and verification labels appear alongside the findings.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
One card from the complete issue